Reviewer’s report

Title: Ticagrelor and clopidogrel suppress NF-kB signaling pathway to alleviate LPS-induced dysfunction in vein endothelial cells

Version: 1 Date: 20 Sep 2019

Reviewer: Mette Bjerre

Reviewer's report:

Please include all comments for the authors in this box rather than uploading your report as an attachment. Please only upload as attachments annotated versions of manuscripts, graphs, supporting materials or other aspects of your report which cannot be included in a text format.

Please overwrite this text when adding your comments to the authors.

The manuscript by Jia et al. shows that incubations with either ticagrelor or clopidogrel together with LPS in HUVEC cells suppress NF-kB pathway activation through inhibiting phosphorylation of p65 and IKBα degradation. The authors suggest that ticagrelor and clopidogrel may be used for treatment acute coronary syndrome. The study is relevant and interesting.

Minor comments:

Methods:

Please mention the number of setups used for the different methods (n=3)?

Please state the transwell assay used for cell migration.

Results (Figure2 and 4):

Figure 2B: legend should be changed to clopidogrel.

Error bars are missing in Fig 2B (4B) and 2D (4D) - please mention number of experimental setup repeats (n=) - looking at the figures one may get the impression that the experiment is only performed once - if that is the case I recommend that the experiments are repeated 3 times as described in Figure 1 and Figure 3.
What is relative intensity refereeing to? protein/GAPDH.

I suggest that figure B and D are shown relative to control (DMSO) - which will improve the readability and show fold changes instead.

Limitations:

Please include your thoughts of study limitations and how the results may translate into treatment.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable
**Declaration of competing interests**

Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal